The management of thrombosis in pregnancy: Role of low-molecular-weight heparin

Summary

Fatal pulmonary embolism remains the most common cause of mortality among pregnant women in many Western countries. The physiological changes of pregnancy produce a hypercoagulable state that increases the risk of venous thromboembolism (VTE).Women with inherited or acquired thrombophilias are at particularly high risk of VTE during pregnancy, and thromboprophylaxis may be advisable in some cases. Thrombophilia is also associated with complications of pregnancy, including fetal loss, pre-eclampsia, intra-uterine growth restriction, and placental abruption. The antithrombotic agents available for the prevention and treatment of VTE during pregnancy, and pregnancy complications, include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and aspirin. Vitamin K antagonists are contra-indicated in pregnancy. Low-dose aspirin may have a role in the prevention of some pregnancy complications, although its safety in early and late pregnancy is uncertain. The efficacy and safety of LMWHs have been demonstrated for the prevention and treatment of VTE in pregnancy. These agents are increasingly being used in place of UFH, which is associated with a higher incidence of side effects compared with LMWH, in addition to the need for regular laboratory monitoring. Evidence is also emerging to support the use of LMWH in the prevention of recurrent fetal loss, although further trials are needed to explore the role of LMWHs in this indication and in the prevention of other complications of pregnacy.

Keywords

Pregnancy - low-molecular-weight heparin - thrombophilia - venous thrombosis

• References

• 1 Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and genecology: the Scottish experience. Scot Med J 1996; 41: 83-86.
• 2 Högberg U, Innala E, Sandström A. Maternal mortality in Sweden. Obstet Gynecol 1995; 84: 240-244.
• 3 Högberg U, Innala E, Sandström A. Report on confidential inquiries into maternal deaths in UK 1994–1996. HMSO (London): 1998: 84
• 4 Athrash HK, Koonin LM, Lawson HW. et al. Maternal morbidity in the United States 1979–1986. Obstet Gynaecol 1990; 76: 1055-1060.
• 5 Rutheford S, Montoro M, McGehee W. et al. Thromboembolic disease associated with pregnancy: an 11 year review. Am J Obstet Gynecol 1991; 164: 286 Suppl abstract
• 6 Lindhagen A, Bergqvist A, Bergqvist D. et al. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. Br J Obst Gynaecol 1986; 93: 348-352.
• 7 Eldor A. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. Eur J Obstet Gynaecol – Reprod Biol 2002; 104: 3-13.
• 8 Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003; 138: 128-134.
• 9 Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-1353.
• 10 Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104: 191-197.
• 11 Clarke P, Brennand J, Conkie JA. et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170.
• 12 Stirling Y, Woolf L, North WRS. et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-180.
• 13 Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium: I. Normal condition. Gynecol Obstet Invest 1981; 12: 141-146.
• 14 Eichinger S, Weltermann A, Philipp K. et al. Prospective evaluation of haemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999; 82: 1232-1236.
• 15 Hoke M, Kyrle PA, Philipp K. et al. Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin. Thromb Haemost 2004; 91: 935-940.
• 16 Holmes VA, Wallace JMW, Gilnmore WS. et al. Tissue factor expression on monocyte subpopulations during normal pregnancy. Thromb Haemost 2002; 87: 953-958.
• 17 Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221-226.
• 18 Nilsson IM, Felding P, Lecander I. et al. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br J Haematol 1986; 62: 215-219.
• 19 Ballegeer V, Mombaerts P, Declerk PJ. et al. Fibrinolytic response to venous occlusion and fibrin fragment D-Dimer levels in normal and complicated pregnancy. Thromb Haemost 1987; 58: 1030-1036.
• 20 Bates SM, Greer I, Hirsh J. et al. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 627S-644S.
• 21 Robertson L, Wu O, Langhorne h P. et al. for The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005; 132: 171-196.
• 22 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-1265.
• 23 Bonnar J. Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism?. Am J Obstet Gynecol 1999; 180: 784-791.
• 24 Conard J. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. J Thromb Haemost 2004; 2: 1190-1193.
• 25 Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Survey 1999; 54: 265-271.
• 26 Weiner Z, Younis JS, Blumenfeld Z. et al. Assessment of uterine placental circulation in thrombophilic women. Semin Thromb Hemost 2003; 29: 213-218.
• 27 Sanson BJ, Friederich PW, Simioni P. et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women. Thromb Haemost 1996; 75: 387-388.
• 28 Branch DW, Silver RM, Blackwell JL. et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80: 614-620.
• 29 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
• 30 Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E. et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control “NOHA first” study. J Thromb Haemost 2005; 3: 2178-2184.
• 31 De Vries JIP, Dekker J, Huijgens PC. et al. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104: 1248-1254.
• 32 Rotmensch S, Liberati M, Mittleman M. et al. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol 1997; 177: 170-173.
• 33 Dizon-Townson DS, Nelson LM, Easton K. et al. The factor V Leiden mutation may predispose women to severe pre-eclampsia. Am J Obstet Gynaecol 1996; 175: 902-905.
• 34 Grandone E, Margagilione M, Colazzo D. et al. FactorV Leiden. C>TMTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Haemost 1997; 77: 1052-1054.
• 35 Lindqvist PG, Svensson PJ, Dahlback B. et al. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss-a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
• 36 Kupferminc MJ, Amiram E, Steinman N. et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 1: 9-13.
• 37 Alferivic S, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome?. Eur J Obstet Gynaecol Reprod Biol 2002; 101: 6-14.
• 38 Morrison ER, Miedzybrodzka ZH, Campbell D. et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-785.
• 39 Brenner B. Thrombophilia and fetal loss. Semin Thromb Haemost 2003; 29: 165-170.
• 40 Long AA, Ginsberg JS, Brill-Edwards P. et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991; 66: 520-524.
• 41 Ginsberg JS, Brill-Edwards P, Johnston M. et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood 1992; 80: 975-980.
• 42 Schaefer C, Hannemann D, Meister R. et al. Vitamin K antagonists and pregnancy outcome. A multicentre prospective study. Thromb Haemost 2006; 95: 949-957.
• 43 Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-31S.
• 44 Weitz JL. Low molecular weight heparins. N Engl J Med 1997; 337: 688-698.
• 45 Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millenium. Semin Thromb Hemost 2000; 26 (Suppl. 01) Suppl 5-21.
• 46 Hoppensteadt D, Walenga JM, Fareed J. et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am 2003; 17: 313-341.
• 47 Duley L. Aspirin for preventing and treating preeclampsia. Br Med J 1999; 318: 751-752.
• 48 Blombäck M, Bremme K, Hellgren M. et al. A pharmacokinetic study of dalteparin Fragmin) during late pregnancy. Blood Coag Fibrinol 1998; 9: 343-350.
• 49 Casele HL, Laifer SA, Woelkers DA. et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 5: 1113-1117.
• 50 Norris LA, Bonnar J, Smith MP. et al. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 2004; 92: 791-796.
• 51 Sephton V, Farquharson RG, Topping J. et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101: 1307-1311.
• 52 Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. Haemostasis 1994; 24: 55-56.
• 53 Sanson BJ, Lensing AWA, Prins MH. et al. Safety of low-molecular-weight heparin in pregnancy – a systematic review. Thromb Haemost 1999; 81: 668-672.
• 54 Lepercq J, Conard J, Borel-Derlon A. et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynecol 2001; 108: 1134-1140.
• 55 Laurent P, Dussarat GV, Bonal J. et al. Low molecular weight heparins – a guide to their optimum use in pregnancy. Drugs 2002; 62: 463-477.
• 56 Ginsberg JS, Hirsh J, Turner DC. et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemostasis 1989; 161: 197-203.
• 57 EUROCAT Working Group. EUROCAT Report 7. 15 years of surveillance of congenital anomalies en. Europe 1994; 1980: 1997
• 58 US Department of Health and Human Services. Food and Drug Administration, Washington DC. Guidance for Industry. Establishing Pregnancy Registries (Draft Guidance). June. 1999
• 59 Greer I, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.
• 60 Selo-Ojeme DO. Primary postpartum haemorrhage. J Obstet Gynaecol 2002; 22: 463-469.
• 61 El-Refaey H, Rodeck C. Post-partum haemorrhage: definitions, medical and surgical management. A time for a change. Br Med Bull 2003; 67: 205-217.
• 62 Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114: 524S-530S.
• 63 Warkentin TE, Levine MN, Hirsh J. et al. Heparininduced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 64 Lindhoff-Last E, Kreutzenback HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93: 63-69.
• 65 Wijesiriwardana A, Lees DA, Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis 2006; 17: 147-149.
• 66 Mazzolai L, Hohlfeld P, Spertini F. et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570.
• 67 Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914-1915.
• 68 de Swiet M, Ward PD, Fiddler J. et al. Prolonged heparin in pregnancy causes bone demineralisation (heparin- induced osteopenia). Br J Obstet Gynaecol 1983; 90: 1129-1134.
• 69 Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment : a radiological study post partum. Br J Obstet Gynaecol 1990; 97: 221-228.
• 70 Dahlman T, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170: 1315-1319.
• 71 Barbour LA, Kick SD, Steiner JF. et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gyn 1994; 170: 862-869.
• 72 Douketis JD, Ginsberg JS, Burrows RD. et al. The effects of long-term heparin therapy on bone density: a prospective matched cohort study. Thromb Haemost 1996; 75: 254-257.
• 73 Murray WJ, Lindo VS, Kakkar VV. et al. Long-term administrations of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul Fibrinolysis 1995; 6: 113-118.
• 74 Melissari E, Parker CJ, Wilson NV. et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-656.
• 75 Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171-174.
• 76 Nelson-Piercy C, Letsky EA, de Swiet M. Low Molecular Weight Heparin for Obstetric Thromboprophylaxis: experience of 69 pregnancies in 61 high risk women. Am J Obstet Gynecol 1997; 176: 1062-1068.
• 77 Hunt BJ, Doughty HA, Majumdar G. et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997; 77: 39-43.
• 78 Pettila V, Leinonen P, Markkola A. et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-186.
• 79 Blombäck M, Bremme K, Hellgren M. et al. Thromboprophylaxis with low molecular mass heparin, Fragmin^® (dalteparin), during pregnancy – a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9: 1-9.
• 80 Hunt BJ, Gattens M, Khamashta M. et al. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis 2003; 14: 735-739.
• 81 Pettila V, Kaaja R, Leinonen P. et al. Thromprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96: 275-282.
• 82 Gates S, Brocklehurst P, Ayers S. et al. Thromprophylaxis and pregnancy: two randomized controlled pilot trials that used low molecular weight heparin. Am J Obstet Gynecol 2004; 191: 1296-1303.
• 83 Gris JC, Mercier E, Quere I. et al. Low molecular weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
• 84 Brenner B, Hoffman R, Carp H. et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss; the LIVEENOX study. J Thromb Haemost 2005; 3: 227-229.
• 85 Lindqvist PG, Merlo J. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence?. Thromb Haemost 2005; 3: 221-223.
• 86 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
• 87 Rai R, Cohen H, Dave M. et al. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.
• 88 Bakos M, Rai R, Baxter N. et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999; 106: 102-107.
• 89 Knight M, Duley L, Hendersen-Smart DJ. et al. Antiplatelet agents for preventing and treating preeclampsia. Cochrane Database Syst Rev 2000; 2: CD000492
• 90 Kupferminc MJ, Fait G, Many A. et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy 2001; 20: 35-44.
• 91 Ulander VM, Stenqvist P, Kaaja R. Treatment of deep venous thrombosis with low molecular weight heparin during pregnancy. Thromb Res 2002; 106: 13-17.
• 92 Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024-1029.
• 93 Rodie VA, Thomson AJ, Stewart FM. et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG 2002; 109: 1020-1024.